A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group.
Snydman
D R
DR
Department of Medicine, New England Medical Center, Boston, MA 02111.
Werner
B G
BG
Dougherty
N N
NN
Griffith
J
J
Rohrer
R H
RH
Freeman
R
R
Jenkins
R
R
Lewis
W D
WD
O'Rourke
E
E
D000212:Acyclovir / Q000627:therapeutic use; D000328:Adult; D001900:Boston; D002177:Candidiasis / Q000209:etiology; D002648:Child; D003587:Cytomegalovirus / Q000276:immunology* / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009894:Opportunistic Infections / Q000209:etiology; D010919:Placebos; D011024:Pneumonia, Viral / Q000209:etiology; D012307:Risk Factors; D016896:Treatment Outcome
D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D010919:Placebos; C045781:cytomegalovirus-specific hyperimmune globulin; D015774:Ganciclovir; D000212:Acyclovir